Results 201 to 210 of about 3,597,090 (249)

Cardiovascular Adverse Events Associated With Carfilzomib, Bortezomib, and Ixazomib: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database With Anticancer Agents as the Reference Group. [PDF]

In Vivo
Fujiwara M, Nagano S, Uesawa Y, Uchida M, Muroi N, Shimizu T.   +5 more
europepmc   +1 more source

National recommendations of the Working Group for Postanalytics of the Croatian Society of Medical Biochemistry and Laboratory Medicine: Quality indicators of the postanalytical phase. [PDF]

Biochem Med (Zagreb)
Podolar S, Vlašić Tanasković J, Jokić A, Honović L, Rimac V, Leniček Krleža J.   +5 more
europepmc   +1 more source

Characteristics of published mini and rapid health technology assessments reports: a cross-sectional analysis. [PDF]

Int J Technol Assess Health Care
McLaughlin S, Abeer A, Sharp MK, Walsh KA, Nemzoff C, Foley S, Clifton E, Flood M, Spillane S, Harrington P, Teljeur C, O'Neill M, Smith SM, Ryan M, Clyne B.   +14 more
europepmc   +1 more source

Comprehensive post-marketing safety evaluation of atezolizumab: A disproportionality analysis based on individual case safety reports in the FAERS. [PDF]

PLoS One
Cui Y, Gao Y, Meng N, Li X, Zhao N, Yu L.   +5 more
europepmc   +1 more source

Clinical Safety of Gadoxetate Disodium: Insights From 20 Years of Use and More Than 12 Million Administrations. [PDF]

Invest Radiol
Endrikat J, Bogosavljev B, Bhatti A, Forgia S, Fuksbrumer MS, Kim S.   +5 more
europepmc   +1 more source

Leveraging Syndromic Surveillance for Rabies Postexposure Prophylaxis Surveillance in Maine, 2018-2022. [PDF]

Public Health Rep
Lamere L, Sohail H, Robinson S.
europepmc   +1 more source